nach oben

Cardiovascular Toxicology

Erschienen in:

09.04.2020 | Collagen

TRPV4 Mediates Cardiac Fibrosis via the TGF-β1/Smad3 Signaling Pathway in Diabetic Rats

verfasst von: Xiaoli Jia, Chao Xiao, Deqiao Sheng, Mengcheng Yang, Quanyi Cheng, Jing Wu, Shizhong Zhang

Erschienen in: Cardiovascular Toxicology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Emerging evidence shows that the transient receptor potential vanilloid 4 (TRPV4) channel is involved in fibrosis in many organs. However, its role in diabetic cardiac fibrosis remains unclear. Our aim was to evaluate the expression level of TRPV4 in the diabetic heart and clarify its role in diabetes-induced cardiac fibrosis. A diabetic animal model was induced by a single intraperitoneal injection of streptozotocin into Sprague–Dawley rats. We also investigated cardiac fibroblasts isolated from neonatal Sprague–Dawley rats. TRPV4 expression was significantly upregulated in both diabetic myocardium and cardiac fibroblasts cultured in high-glucose medium. Masson’s trichrome staining revealed that the TRPV4 antagonist HC067047 attenuated the diabetes-induced cardiac fibrosis. Furthermore, HC067047 reduced collagen Ι synthesis and suppressed the transforming growth factor beta 1 (TGF-β1) level as well as the phosphorylation of Smad3 in the diabetic heart. In addition, the TRPV4 antagonist inhibited the proliferation of cardiac fibroblasts, collagen Ι synthesis, and activation of the TGF-β1/Smad3 signaling pathway induced by high-glucose culture medium. Our findings demonstrate that the upregulation of TRPV4 expression mediates diabetic cardiac fibrosis via activation of the TGF-β1/Smad3 signaling pathway.

Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., et al. (2016). Heart disease and stroke statistics-2016 Update: A report from the American Heart Association. Circulation, 133(4), e38–360. https://doi.org/10.1161/CIR.0000000000000350.CrossRefPubMed

Plutzky, J. (2011). Macrovascular effects and safety issues of therapies for type 2 diabetes. The American Journal of Cardiology, 108(3 Suppl), 25B–32B. https://doi.org/10.1016/j.amjcard.2011.03.014.CrossRefPubMed

Shao, S., Zhang, X., Duan, L., Fang, H., Rao, S., Liu, W., et al. (2018). Lysyl Hydroxylase Inhibition by Minoxidil Blocks Collagen Deposition and Prevents Pulmonary Fibrosis via TGF-beta(1)/Smad3 Signaling Pathway. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 24, 8592–8601. https://doi.org/10.12659/MSM.910761.CrossRef

Adameova, A., & Dhalla, N. S. (2014). Role of microangiopathy in diabetic cardiomyopathy. Heart Failure Reviews, 19(1), 25–33. https://doi.org/10.1007/s10741-013-9378-7.CrossRefPubMed

Joshi, M., Kotha, S. R., Malireddy, S., Selvaraju, V., Satoskar, A. R., Palesty, A., et al. (2014). Conundrum of pathogenesis of diabetic cardiomyopathy: Role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria. Molecular and Cellular Biochemistry, 386(1–2), 233–249. https://doi.org/10.1007/s11010-013-1861-x.CrossRefPubMed

Ather, S., Chan, W., Bozkurt, B., Aguilar, D., Ramasubbu, K., Zachariah, A. A., et al. (2012). Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. Journal of the American College of Cardiology, 59(11), 998–1005. https://doi.org/10.1016/j.jacc.2011.11.040.CrossRefPubMedPubMedCentral

Paulus, W. J., & Tschope, C. (2013). A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology, 62(4), 263–271. https://doi.org/10.1016/j.jacc.2013.02.092.CrossRefPubMed

Chacar, S., Fares, N., Bois, P., & Faivre, J.-F. (2017). Basic Signaling in Cardiac Fibroblasts. Journal of Cellular Physiology, 232(4), 725–730. https://doi.org/10.1002/jcp.25624.CrossRefPubMed

Camelliti, P., Borg, T. K., & Kohl, P. (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovascular Research, 65(1), 40–51. https://doi.org/10.1016/j.cardiores.2004.08.020.CrossRefPubMed

10.

Liu, Y., Qi, H., Mingyao, E., Shi, P., Zhang, Q., Li, S., et al. (2018). Transient receptor potential vanilloid-3 (TRPV3) activation plays a central role in cardiac fibrosis induced by pressure overload in rats via TGF-beta1 pathway. Naunyn Schmiedebergs Archives of Pharmacology, 391(2), 131–143. https://doi.org/10.1007/s00210-017-1443-7.CrossRefPubMed

11.

Ruppert, M., Bodi, B., Korkmaz-Icoz, S., Loganathan, S., Jiang, W., Lehmann, L., et al. (2019). Myofilament Ca(2+) sensitivity correlates with left ventricular contractility during the progression of pressure overload-induced left ventricular myocardial hypertrophy in rats. Journal of Molecular and Cellular Cardiology, 129, 208–218. https://doi.org/10.1016/j.yjmcc.2019.02.017.CrossRefPubMed

12.

Roe, A. T., Aronsen, J. M., Skardal, K., Hamdani, N., Linke, W. A., Danielsen, H. E., et al. (2017). Increased passive stiffness promotes diastolic dysfunction despite improved Ca2+ handling during left ventricular concentric hypertrophy. Cardiovascular Research, 113(10), 1161–1172. https://doi.org/10.1093/cvr/cvx087.CrossRefPubMedPubMedCentral

13.

Suarez, J., Cividini, F., Scott, B. T., Lehmann, K., Diaz-Juarez, J., Diemer, T., et al. (2018). Restoring mitochondrial calcium uniporter expression in diabetic mouse heart improves mitochondrial calcium handling and cardiac function. The Journal of Biological Chemistry, 293(21), 8182–8195. https://doi.org/10.1074/jbc.RA118.002066.CrossRefPubMedPubMedCentral

14.

Zhang, L., Ward, M.-L., Phillips, A. R. J., Zhang, S., Kennedy, J., Barry, B., et al. (2013). Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats. Cardiovascular Diabetology, 12, 123. https://doi.org/10.1186/1475-2840-12-123.CrossRefPubMedPubMedCentral

15.

Choi, K. M., Zhong, Y., Hoit, B. D., Grupp, I. L., Hahn, H., Dilly, K. W., et al. (2002). Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. American Journal of Physiology Heart and Circulatory Physiology, 283(4), H1398–H1408. https://doi.org/10.1152/ajpheart.00313.2002.CrossRefPubMed

16.

Li, H. (2017). TRP channel classification. Advances in Experimental Medicine and Biology, 976, 1–8. https://doi.org/10.1007/978-94-024-1088-4_1.CrossRefPubMed

17.

Adapala, R. K., Thoppil, R. J., Luther, D. J., Paruchuri, S., Meszaros, J. G., Chilian, W. M., et al. (2013). TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. Journal of Molecular and Cellular Cardiology, 54, 45–52. https://doi.org/10.1016/j.yjmcc.2012.10.016.CrossRefPubMed

18.

Liu, Y., Qi, H., Miangyao, E., Shi, P., Zhang, Q., Li, S.,& Sun, H., (2018). Transient receptor potential vanilloid-3 (TRPV3) activation plays a central role in cardiac fibrosis induced by pressure overload in rats via TGF-beta1 pathway. Naunyn-Schmiedeberg’s Archives of Pharmacology, 391(2), 131–143. https://doi.org/10.1007/s00210-017-1443-7.

19.

Heymann, H. M., Wu, Y., Lu, Y., Qvit, N., Gross, G. J., & Gross, E. R. (2017). Transient receptor potential vanilloid 1 inhibitors block laparotomy- and opioid-induced infarct size reduction in rats. British Journal of Pharmacology, 174(24), 4826–4835. https://doi.org/10.1111/bph.14064.CrossRefPubMedPubMedCentral

20.

Filosa, J. A., Yao, X., & Rath, G. (2013). TRPV4 and the regulation of vascular tone. Journal of Cardiovascular Pharmacology, 61(2), 113–119. https://doi.org/10.1097/FJC.0b013e318279ba42.CrossRefPubMedPubMedCentral

21.

Darby, W. G., Grace, M. S., Baratchi, S., & McIntyre, P. (2016). Modulation of TRPV4 by diverse mechanisms. The International Journal of Biochemistry & Cell Biology, 78, 217–228. https://doi.org/10.1016/j.biocel.2016.07.012.CrossRef

22.

Martinac, B., & Poole, K. (2018). Mechanically activated ion channels. The International Journal of Biochemistry & Cell Biology, 97, 104–107. https://doi.org/10.1016/j.biocel.2018.02.011.CrossRef

23.

Randhawa, P. K., & Jaggi, A. S. (2015). TRPV4 channels: Physiological and pathological role in cardiovascular system. Basic Research in Cardiology, 110(6), 54. https://doi.org/10.1007/s00395-015-0512-7.CrossRefPubMed

24.

Wu, Q.-F., Qian, C., Zhao, N., Dong, Q., Li, J., Wang, B.-B., et al. (2017). Activation of transient receptor potential vanilloid 4 involves in hypoxia/reoxygenation injury in cardiomyocytes. Cell Death & Disease, 8(5), e2828. https://doi.org/10.1038/cddis.2017.227.CrossRef

25.

Dong, Q., Li, J., Wu, Q.-F., Zhao, N., Qian, C., Ding, D., et al. (2017). Blockage of transient receptor potential vanilloid 4 alleviates myocardial ischemia/reperfusion injury in mice. Scientific Reports, 7, 42678. https://doi.org/10.1038/srep42678.CrossRefPubMedPubMedCentral

26.

Zhan, L., & Li, J. (2018). The role of TRPV4 in fibrosis. Gene, 642, 1–8. https://doi.org/10.1016/j.gene.2017.10.067.CrossRefPubMed

27.

Rahaman, S. O., Grove, L. M., Paruchuri, S., Southern, B. D., Abraham, S., Niese, K. A., et al. (2014). TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. The Journal of Clinical Investigation, 124(12), 5225–5238. https://doi.org/10.1172/JCI75331.CrossRefPubMedPubMedCentral

28.

Gombedza, F., Kondeti, V., Al-Azzam, N., Koppes, S., Duah, E., Patil, P., et al. (2017). Mechanosensitive transient receptor potential vanilloid 4 regulates Dermatophagoides farinae-induced airway remodeling via 2 distinct pathways modulating matrix synthesis and degradation. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 31(4), 1556–1570. https://doi.org/10.1096/fj.201601045R.CrossRef

29.

Songa, Y., Zhan, L., Yu, M., Huang, C., Meng, X., Taotao, M., et al. (2014). TRPV4 channel inhibits TGF-β1-induced proliferation of hepatic stellate cells. PLoS ONE, 9(7), 1–10. https://doi.org/10.1371/journal.pone.0101179.CrossRef

30.

Feng, B., Chen, S., George, B., Feng, Q., & Chakrabarti, S. (2010). miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes/Metabolism Research and Reviews, 26(1), 40–49. https://doi.org/10.1002/dmrr.1054.CrossRefPubMed

31.

Shen, E., Diao, X., Wang, X., Chen, R., & Hu, B. (2011). MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. The American Journal of Pathology, 179(2), 639–650. https://doi.org/10.1016/j.ajpath.2011.04.034.CrossRefPubMedPubMedCentral

32.

Hu, H.-H., Chen, D.-Q., Wang, Y.-N., Feng, Y.-L., Cao, G., Vaziri, N. D., et al. (2018). New insights into TGF-beta/Smad signaling in tissue fibrosis. Chemico-Biological Interactions, 292, 76–83. https://doi.org/10.1016/j.cbi.2018.07.008.CrossRefPubMed

Titel: TRPV4 Mediates Cardiac Fibrosis via the TGF-β1/Smad3 Signaling Pathway in Diabetic Rats
verfasst von: Xiaoli Jia
Chao Xiao
Deqiao Sheng
Mengcheng Yang
Quanyi Cheng
Jing Wu
Shizhong Zhang
Publikationsdatum: 09.04.2020
Verlag: Springer US
Schlagwörter: Collagen
Diabetes
Erschienen in: Cardiovascular Toxicology / Ausgabe 5/2020
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-020-09572-8

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

TRPV4 Mediates Cardiac Fibrosis via the TGF-β1/Smad3 Signaling Pathway in Diabetic Rats

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

The Cardioprotective Effects of Aminoguanidine on Lipopolysaccharide Induced Inflammation in Rats

The Case of Myocardial Infarction in a Fifteen-Year-Old Adolescent Caused by Toxic Substances

COVID-19: A Concern for Cardiovascular Disease Patients

Role of Peroxiredoxins in Protecting Against Cardiovascular and Related Disorders

Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases

Ergosterol Attenuates Isoproterenol-Induced Myocardial Cardiotoxicity